Drug ID:Drug111
Drug Name:Dapagliflozin
CID:9887712
DrugBank ID:DB06292
Modality:Small Molecule
Groups:approved
US Approved:YES
Other Approved:YES
Identifier: NCT05986136
Molecular Formula:C21H25ClO6
Molecular Weight:408.9 g/mol
Isomeric SMILES:CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)Cl
Synonyms:Dapagliflozin; 461432-26-8; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; dapagliflozine; Dapagliflozina; UNII-1ULL0QJ8UC; 1ULL0QJ8UC; CHEBI:85078; LYN-045; DTXSID20905104
Phase 0: 5
Phase 1: 124
Phase 2: 113
Phase 3: 175
Phase 4: 176
Description:Dapagliflozin is indicated for the management of diabetes mellitus type 2, and functions to improve glycemic control in adults when combined with diet and exercise. Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor, which prevents glucose reabsorption in the kidney. Using dapagliflozin leads to heavy glycosuria (glucose excretion in the urine), which can lead to weight loss and tiredness. Dapagliflozin was approved by the FDA on Jan 08, 2014. Dapagliflozin is not recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt938 9887712 Dapagliflozin 26762 HAVCR1 Rattus norvegicus (Norway rat) 30551545 Dapagliflozin promotes the reaction [metformin inhibits the reaction [[streptozocin co-treated with fructose] results in increased expression of HAVCR1 protein]]|dapagliflozin inhibits the reaction [[streptozocin co-treated with fructose] results in incre
dt939 9887712 Dapagliflozin 3146 HMGB1 Rattus norvegicus (Norway rat) 33412153 Dapagliflozin inhibits the reaction [trinitrobenzenesulfonic acid results in increased expression of HMGB1 protein]
dt940 9887712 Dapagliflozin 3162 HMOX1 Rattus norvegicus (Norway rat) 32259528 Dapagliflozin inhibits the reaction [[fructose co-treated with dietary fats] results in decreased expression of HMOX1 protein]|[atorvastatin co-treated with dapagliflozin] inhibits the reaction [[fructose co-treated with dietary fats] results in decreased
dt941 9887712 Dapagliflozin 3162 HMOX1 Rattus norvegicus (Norway rat) 38997059 Dapagliflozin inhibits the reaction [doxorubicin results in decreased expression of HMOX1 mrna]
dt942 9887712 Dapagliflozin 3162 HMOX1 Rattus norvegicus (Norway rat) 33412153 Dapagliflozin inhibits the reaction [trinitrobenzenesulfonic acid results in decreased expression of HMOX1 protein]
dt943 9887712 Dapagliflozin 3309 HSPA5 Rattus norvegicus (Norway rat) 37741535 Dapagliflozin inhibits the reaction [IL1B protein results in increased expression of HSPA5 mrna]
dt944 9887712 Dapagliflozin 3586 IL10 Rattus norvegicus (Norway rat) 33412153 Dapagliflozin inhibits the reaction [trinitrobenzenesulfonic acid results in decreased expression of IL10 protein]
dt945 9887712 Dapagliflozin 3600 IL15 Rattus norvegicus (Norway rat) 33882723 Taxifolin promotes the reaction [dapagliflozin inhibits the reaction [colistin results in increased expression of IL15 protein]]|dapagliflozin inhibits the reaction [colistin results in increased expression of IL15 protein]
dt946 9887712 Dapagliflozin 3553 IL1B Rattus norvegicus (Norway rat) 34939712 [dapagliflozin co-treated with atorvastatin] inhibits the reaction [[dietary fats co-treated with fructose] results in increased expression of IL1B protein]
dt947 9887712 Dapagliflozin 3553 IL1B Rattus norvegicus (Norway rat) 37741535 Dapagliflozin inhibits the reaction [IL1B protein results in increased expression of ADAMTS5 protein]|[thapsigargin co-treated with dapagliflozin] inhibits the reaction [IL1B protein results in increased expression of BAX protein]|dapagliflozin inhibits t

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT05986136 Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease PHASE2|PHASE3 RECRUITING Mostafa Bahaa Inflammatory Bowel Diseases DRUG: Mesalamine|DRUG: Dapagliflozin 10mg Tab Details
KCT0008022 The effect of preconception care program for women with inflammatory bowel disease: a mixed method study Not Available Not Recruiting University of Ulsan ;Diseases of the digestive system Behavioral, Others(Education) : The experimental … Details
NL-OMON49003 A randomised controlled trial comparing FMT (fecal microbiota transplantation) after budesonide or placebo in patients with active ulcerative colitis: ;Acronym: the FECBUD trial __ - FMT for ulcerative colitis after initiation of budesonide Not Available Not Recruiting Leids Universitair Medisch Centrum inflammatory bowel disease ulcerative colitis;10… Intervention Patients with active ulcerative coli… Details
NL-OMON44482 A randomised controlled trial comparing FECal Microbiota Transplantation after BUDesonide or placebo induction in patients with ulcerative colitis; the FECBUD trial__ - FMT for ulcerative colitis after initiation of budesonide Not Available None Haaglanden Medisch Centrum inflammatory bowel disease ulcerative colitis;10… Intervention Patients with active ulcerative coli… Details
CTRI/2017/10/010160 Evaluation of a Peri-Operative Low Dose Steroid Regimen for Steroid Treated Inflammatory Bowel Disease patients A Prospective Randomised Study PHASE2|PHASE3 Recruiting AIIMS Health Condition 1: null- patient having infalmma… Intervention1: Low dose Steroid (LDS) Regimen: Pa… Details
NCT03863886 Endoscopic Ultrasound Determines Disease Activity in Crohn's Disease And Ulcerative Colitis None UNKNOWN Carilion Clinic Crohn Disease|Ulcerative Colitis PROCEDURE: Endoscopic ultrasound catheter (UM-2R/… Details
NCT05575505 Phosphodiesterase Inhibitors, Pentoxifylline, as Adjunctive Therapy in Patients With Ulcerative Colitis. PHASE2 RECRUITING Tanta University Inflammatory Bowel Diseases DRUG: Pentoxifylline 400 MG Details
NCT06651281 Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011) PHASE3 RECRUITING Merck Sharp & Dohme LLC Crohn Disease|Colitis, Ulcerative DRUG: Tulisokibart|DRUG: Placebo to tulisokibart Details
NCT06681181 A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK4528287 in Healthy Participants PHASE1 RECRUITING GlaxoSmithKline Colitis, Ulcerative DRUG: GSK4528287|DRUG: Placebo Details
NCT04478825 Efficacy and Safety of Rectally Administered BBT-401-1S in Subjects With Ulcerative Colitis PHASE1 TERMINATED Bridge Biotherapeutics, Inc. Ulcerative Colitis DRUG: BBT-401-1S Details
NCT06321887 EffiCacy and sAfEty of Low doSe orAl iRon for Anaemia in IBD PHASE3 RECRUITING Liverpool University Hospitals NHS Foundation Trust Inflammatory Bowel Disease|Iron Deficiency Anemia DRUG: Ferrous fumarate syrup 2.5ml/70mg (22.5mg e… Details
NCT02447302 Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis PHASE2 COMPLETED Arena Pharmaceuticals Ulcerative Colitis DRUG: Etrasimod|DRUG: Placebo Details
NCT05507203 ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 PHASE3 RECRUITING Abivax S.A. Ulcerative Colitis DRUG: ABX464|DRUG: Placebo Details
NCT04677179 A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) PHASE2 TERMINATED Nektar Therapeutics Colitis, Ulcerative DRUG: LY3471851|DRUG: Placebo Details
NCT05177835 Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis PHASE2 ACTIVE_NOT_RECRUITING Abivax S.A. Ulcerative Colitis DRUG: ABX464 Details
NCT04348890 Proof of Concept Trial of Vamorolone in Pediatric Ulcerative Colitis PHASE1|PHASE2 WITHDRAWN ReveraGen BioPharma, Inc. Pediatric Ulcerative Colitis DRUG: Vamorolone 4% suspension for oral dosing Details
NCT02958865 Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis PHASE2 COMPLETED Pfizer Ulcerative Colitis DRUG: PF-06651600 or Placebo|DRUG: PF-06700841 or… Details
NCT03943550 Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC) PHASE1 TERMINATED Hoffmann-La Roche Ulcerative Colitis DRUG: RO7049665|DRUG: Placebo Details
NCT02840721 Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis. PHASE2 COMPLETED Telavant, Inc. Colitis, Ulcerative DRUG: PF-06480605 Details
NCT05907330 Phase 2 Study of CU104 in Moderate-Severe Ulcerative Colitis PHASE2 NOT_YET_RECRUITING Curacle Co., Ltd. Ulcerative Colitis DRUG: CU104|DRUG: Placebo Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
S06 Anti-fibrosis fibrosis; tissue remodelling GS-5745; STNM01 Tissue remodelling and destruction in patients with IBD is … Details
S07 Blockade of cytokine Cytokine signalling apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab Various T-cell subsets, their differentiation pathways and … Details

No related literature

You can run management commands to establish drug-literature associations